CTLA 4 News and Research

RSS

New screening method can rapidly discover potential cancer-treating compounds

Scientists at Scripps Research have developed a method for rapidly discovering potential cancer-treating compounds that work by resurrecting anti-tumor activity in immune cells called T cells.

3 Dec 2019

Streamlining Immuno-Oncological Therapeutic Antibody Discovery

The growing trend of implementing immunotherapy into oncology has resulted in various new therapeutic cancer treatments utilizing antibodies.

From Sartorius 3 Dec 2019

Study: TBK1 protein promotes cancer development, suppresses immune response to the disease

Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes also can fuel cancer development and suppress immune response to the disease.

3 Dec 2019

Research explains why immunotherapy fails against prostate cancer bone metastases

Prostate cancer that spreads to the bone triggers the destruction of bone tissue that, in turn, thwarts the effectiveness of immune checkpoint inhibitors by blocking the development of T cells that are crucial to successful treatment, researchers from The University of Texas MD Anderson Cancer Center report in Cell.

14 Nov 2019

Cancer patients with RA treated with immune checkpoint inhibitors likely to experience a flare

A new study found that cancer patients with a pre-existing autoimmune disease receiving immune checkpoint inhibitors as treatment are likely to experience a flare.

11 Nov 2019

CRISPR helps find difficult to detect cancer cells

Immunotherapy is one of the latest and most effective armaments against various types of cancers. Some of the immunotherapy drugs such as PD-1 inhibitor Keytruda from Merck can block certain proteins in the cancer cells that can make the cells invisible to the immune system normally. Some of the cancers cells can now develop other ways to disguise themselves from being killed by the immune system.

15 Oct 2019

Mutations linked with sensitivity or resistance to immunotherapy in mNSCLC

The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized.

10 Sep 2019

Age affects efficacy of immunotherapy treatment for breast cancer, preclinical study reveals

Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient's immune system to attack cancer, has been revolutionary in its implications for breast cancer treatment, especially for its potential to treat patients with triple negative breast cancer.

8 Sep 2019

Researchers explore new immune checkpoint for head and neck cancer

A checkpoint may delay travelers but it can help give cancer free rein by suppressing the natural immune response that should destroy it, researchers say.

25 Jun 2019

Combination immunotherapy shows promise in pre-surgical setting for early-stage lung cancers

Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery.

3 Jun 2019

Low-dose radiation therapy may increase uptake of therapeutic nanoparticles by brain tumors

A new study led by Massachusetts General Hospital (MGH) investigators finds that radiation therapy may increase the uptake of therapeutic nanoparticles by glioblastomas, raising the possibility of using both growth-factor-targeted and immune-system-based therapies against the deadly brain tumor.

28 Mar 2019

Castration-resistant metastatic prostate cancer responds to combination of immune checkpoint inhibitors

Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators at The University of Texas MD Anderson Cancer Center presented today at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.

15 Feb 2019

New potential immunotherapy target in pancreatic cancer identified

Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers.

11 Jan 2019

Nobel Laureates lecture about immune checkpoint therapy for cancer treatment

The Nobel Lectures held by the laureates of the 2018 Nobel Prize in Physiology or Medicine saw Aula Medica at Karolinska Institutet filled to the brink. In addition to 1,000 audience members in the auditorium, people around the world were able to watch the live broadcast when James P. Allison and Tasuku Honjo talked about their research, the results of which have led to the ground-breaking immune checkpoint therapy for cancer treatment.

12 Dec 2018

Study sheds new light on microtubule binding proteins and microtubule dynamics

When bacteria or viruses enter the body, proteins on their surfaces are recognized and processed to activate T cells, white blood cells with critical roles in fighting infections.

6 Dec 2018

Study reveals nature of how T cells protect the brain against harmful viruses

Researchers from the Netherlands Institute for Neuroscience and Amsterdam UMC have disclosed the nature of how T cells protect the brain against harmful viruses.

2 Nov 2018

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.

22 Oct 2018

Personal Genome Diagnostics’ pan-cancer assay being used in new clinical trial

Personal Genome Diagnostics, Inc., a leader in cancer genomics and pioneer in liquid biopsy, today reported that its non-invasive, pan-cancer plasma assay is being used in an important new clinical trial, Nivolumab, Ipilimumab in Patients With Hyper Mutated Cancers Detected in Blood, led by the Cancer Research Institute and Canadian Cancer Trials Group.

9 Oct 2018

Neoadjuvant clinical trial of immune checkpoint blockade for melanoma patients yields high response rate

Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early.

8 Oct 2018

Addition of CTLA4 targeted therapy to PD-1 targeted therapy may benefit patients with ovarian cancer

An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival hazard rates for women with recurrent epithelial ovarian cancer.

19 Sep 2018